EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy

Ji-Young Lee, Seong-Beom Lee iD, Suk-Woo Yang iD, Ji-Sun Paik iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Ji-Young Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Institute of Hansen's Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Cell Proliferation, Insulin-Like Growth Factor I, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Ophthalmology, College of medicine, the Catholic University of Korea, Ki-Soo Kim Research Fund, 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid-associated ophthalmopathy (TAO), an autoimmune disorder of the retrobulbar tissue, is present in up to 50 percent of Graves’s hyperthyroidism patients. Insulin-like growth factor 1 receptor (IGF-1R) has received attention as a target for the development of therapeutic agent for TAO. IGF-1R and TSHR (thyroid stimulating hormone receptor) interact with each other to form a physical or functional complex, further promoting the development of TAO. Linsitinib, OSI-906, is an inhibitor of IGF-1R and has been reported to inhibit cell proliferation of several tumor cells. Linsitinib has been receiving attention not only for its anticancer effect, but also for its anti-inflammatory effects. It has been reported that linsitinib reduces infiltration of inflammatory cells in orbital tissues, resulting in the reduction of muscle edema and adipose tissues in an experimental murine model for Graves’ disease. In the current study, we investigated the issue of whether linsitinib inhibits the IGF-1-induced proliferation of orbital fibroblasts (OFs) via the suppression of phosphatidylinositol 3-kinase (PI3K) / Akt and extracellular signal-regulated kinase (ERK) pathway. Our results showed that pretreatment with linsitinib inhibited IGF-1-induced cell proliferation and hyaluronic acid secretion in the OFs of TAO patients. In addition, our results showed that pretreatment with linsitinib inhibited IGF-1-induced phosphorylation of IGF-1Rβ at Tyr1135, Akt at Ser473, and ERK in the OFs of patients with TAO. These results indicate that linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion in the OFs of TAO patients by suppressing the PI3K/Akt and ERK pathways, validating the use of linsitinib as a novel therapeutic agent for TAO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyCell ProliferationInsulin-Like Growth Factor IProto-Oncogene Proteins c-aktFibroblastsPyrazinesHyaluronic AcidPhosphatidylinositol 3-KinasesReceptor, IGF Type 1MAP Kinase Signaling SystemImidazolesHumansFemaleMaleOrbitMiddle AgedAdultSignal Transduction

Substanzen

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanolInsulin-Like Growth Factor IProto-Oncogene Proteins c-aktPyrazinesHyaluronic AcidPhosphatidylinositol 3-KinasesReceptor, IGF Type 1Imidazoles

Autor:innen und Institutionen

  • Department of Pathology, Institute of Hansen's Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Seong-Beom Lee, Suk-Woo Yang, Ji-Sun Paik

Förderung

  • Department of Ophthalmology, College of medicine, the Catholic University of Korea, Ki-Soo Kim Research Fund, 2023

Zitieren

APA

Lee, J. Y., Lee, S. B., Yang, S. W., & Paik, J. S. (2024). Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. PLOS ONE. https://doi.org/10.1371/journal.pone.0311093

Vancouver

Lee JY, Lee SB, Yang SW, Paik JS. Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. PLOS ONE. 2024. doi:10.1371/journal.pone.0311093

BibTeX
@article{Lee2024,
  author = {Lee, Ji-Young and Lee, Seong-Beom and Yang, Suk-Woo and Paik, Ji-Sun},
  title = {Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311093}
}
Kostenlos starten →